Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years (Q45743589)

15 December 2017

title

Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years (English)

1 reference

15 December 2017

pneumococcal conjugate vaccine

main subject

public health

0 references

vaccine

0 references

1 reference

6

Lisa A Jackson

1 reference

15 December 2017

author name string

Derek Weycker

1

1 reference

15 December 2017

Reiko Sato

2

1 reference

15 December 2017

David Strutton

3

1 reference

15 December 2017

John Edelsberg

4

1 reference

15 December 2017

Mark Atwood

5

1 reference

15 December 2017

language of work or name

English

0 references

publication date

20 June 2012

1 reference

15 December 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

15 December 2017

volume

30

1 reference

15 December 2017

issue

36

1 reference

15 December 2017

page(s)

5437-5444

1 reference

15 December 2017

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Clinical and economic burden of pneumococcal disease in older US adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Predicting bacteremia in patients with community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Treatment costs of community-acquired pneumonia in an employed population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Efficacy of pneumococcal vaccination in adults: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Vaccines for preventing pneumococcal infection in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

Cost-effectiveness of the pneumococcal vaccine in healthy younger adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

6th International Symposium on Pneumococci and Pneumococcal Diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.076

10.1016/J.VACCINE.2012.05.076

7 January 2021

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017